Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
MacroGenics (MGNX) Stock Price & Analysis
583 Followers
MGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.14 - $21.88
Previous Close$4.38
Volume3.66M
Average Volume (3M)2.35M
Market Cap
$283.73M
Enterprise Value$207.35M
Total Cash (Recent Filing)$100.96M
Total Debt (Recent Filing)$33.97M
Price to Earnings (P/E)-11.7
Beta1.45
Next Earnings
Aug 01, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding62,633,460
10 Day Avg. Volume6,578,869
30 Day Avg. Volume2,345,880
Standard Deviation0.30
R-Squared0.13
Alpha0.00991
Financial Highlights & Ratios
Price to Book (P/B)1.35
Price to Sales (P/S)4.67
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$14.56Price Target Upside221.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
MacroGenics News
Bulls Say, Bears Say
Bulls Say
Potential EfficacyVobra Duo's efficacy is supported by the Tamarack trial's results, indicating a strong PSA50 response and overall response rates, bolstering confidence in its potential as a prostate cancer treatment.
Safety And TolerabilityThe Tamarack study demonstrates enhanced safety of Vobra Duo, with a significant reduction in high-grade adverse events and treatment interruptions, suggesting improved patient tolerability.
Strategic PositioningMGNX's B7-H3 targeting ADC franchise, including vobra duo, positions the company strategically in the growing market for metastatic castration-resistant prostate cancer treatments, outside of current AR and PSMA-targeted therapies.
Bears Say
Drug Safety And EfficacyPatient deaths call vobra duo's future into question—lowering price target.
Financial ForecastCutting peak sales estimates to $255M in 2037, significantly down from prior estimates.
Stock RatingDowngrading to Market Perform on Lower Conviction for Prostate Franchise.
---
Ownership Overview
30.98% Insiders
24.47% Mutual Funds
22.73% Other Institutional Investors
21.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $3.14 and its highest was $21.88 in the past 12 months.
What is MacroGenics’s market cap?
Currently, no data Available
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on May 09, 2024. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.643 by -$0.197.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -$0.7.
How many shares outstanding does MacroGenics have?
MacroGenics has 62,633,460 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.643. Following the earnings report the stock price went down -77.437%.
Which hedge fund is a major shareholder of MacroGenics?
Among the largest hedge funds holding MacroGenics’s share is RA Capital Management. It holds MacroGenics’s shares valued at 39M.
---
MacroGenics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.56 (221.41% Upside)
$14.56 (221.41% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.3%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.43%
12-Months-Change
Fundamentals
Return on Equity
-21.58%
Trailing 12-Months
Asset Growth
-27.72%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
MGNX Earnings Call
Q1 2024
0:00 / 0:00
---
MGNX Stock 12 Month Forecast
Average Price Target
$14.56
▲(221.41% Upside)
Technical Analysis
Best Analysts Covering MGNX
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-7.81%
reiterated a buy rating 5 days ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -7.81% per trade.
---